Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 2020

View Archived Issues

NEFAs nefarious role in pancreatitis

Enrollment begins in phase I study of AmnioBoost for treatment of COVID-19

Opioid analgesic CYX-6 displays antinociception without constipation, respiratory depression

Cellenkos seeks to advance CK-0802 for CoV-ARDS

CanSino receives clearance in China for phase I trials with Ad5-nCoV candidate vaccine for COVID-19

SELLAS presents positive data from phase II VADIS study of nelipepimut-S

Mateon to develop OT-101 against COVID-19

Positive final data from phase Ib study of Allocetra-OTS in severe sepsis

Pneumagen announces new program to target COVID-19 infections

Armata awarded up to USD 5 million from CFF for the development AP-PA02

The University of Washington discloses new ERN1/ERN2 inhibitors

Clinical data published on vincristine and irinotecan in children with Wilms tumor

IDO-1 inhibitors discovered at Bristol-Myers Squibb

Testing, testing: first repurposing trial for COVID-19 falls flat

Phase II data reported for preoperative letrozole in DCIS

Zolgensma approved in Japan for SMA

Global phase III trial to evaluate Actemra for severe COVID-19 pneumonia

Researchers identify novel biomarkers in Crohn's disease

Pfizer reports phase III data on 20-valent pneumococcal conjugate vaccine in vaccine-naive adults

Cellphire cleared to begin phase II study of Thrombosomes in bleeding patients with thrombocytopenia

Northwestern University synthesizes new glucosylceramidase modulators

Xenon Pharmaceuticals patents Nav1.6 channel blockers

New antitubercular compounds identified at Monash University

Identification and optimization of isoxazole amides as potent and selective SMYD3 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...